Key Takeaway
Liraglutide 3.0mg side effects with frequency data from the SCALE trials. GI symptoms, serious risks, management strategies, and when to call your physician.
The most common liraglutide 3.0mg side effects are nausea (39.3%), diarrhea (20.9%), constipation (19.4%), and vomiting (15.7%), based on data from the SCALE clinical trial program. These are the exact frequencies reported at the full Saxenda maintenance dose. Most are GI-related, temporary, and manageable with simple strategies. Below we cover every significant side effect, its frequency, and what to do about it.
Complete Side Effect Frequency Table
The following data comes directly from the Saxenda prescribing information, which pooled results from the SCALE clinical trials involving over 3,300 patients on liraglutide 3.0mg.
| Side Effect | Liraglutide 3.0mg | Placebo | Category |
|---|---|---|---|
| Nausea | 39.3% | 13.8% | GI |
| Diarrhea | 20.9% | 9.9% | GI |
| Constipation | 19.4% | 8.5% | GI |
| Vomiting | 15.7% | 3.9% | GI |
| Decreased appetite | 10.0% | 2.3% | Metabolic |
| Dyspepsia | 9.6% | 3.5% | GI |
| Abdominal pain | 5.4% | 3.1% | GI |
| Headache | 13.6% | 12.6% | Neurological |
| Fatigue | 7.5% | 4.6% | General |
| Dizziness | 6.9% | 5.0% | Neurological |
| Increased lipase | 5.3% | 2.2% | Pancreatic marker |
| Injection site reaction | 3.2% | 2.5% | Local |
GI Side Effects in Detail
Nausea: The Most Common Complaint
Nearly 4 in 10 patients experienced nausea at some point during the SCALE trials. But the timing matters. Nausea was most severe during the titration phase and the first 2 to 4 weeks at 3.0mg. By week 8, most patients reported significant improvement. Only 3.5% of patients discontinued liraglutide specifically because of nausea.
View data table
| Category | Mean Body Weight Loss (%) | Detail |
|---|---|---|
| Tirzepatide | 22 | ~22% body weight at 72 wks |
| Semaglutide | 15 | ~15% body weight at 68 wks |
| Liraglutide | 8 | ~8% body weight at 56 wks |
| Retatrutide | 24 | ~24% in Phase 2 trial |
Management: small meals, bland foods, avoiding lying down after eating, staying hydrated, and ginger-based remedies.
Constipation vs. Diarrhea
It may seem contradictory that both constipation (19.4%) and diarrhea (20.9%) are common. This reflects the fact that liraglutide alters gut motility in complex ways. Some patients experience slowed transit (constipation) while others have intermittent loose stools. A small subset cycles between both.
For constipation: fiber, water, physical activity, and stool softeners if needed. For diarrhea: bland diet (BRAT approach), hydration with electrolytes, and avoiding dairy or high-fat foods temporarily.
Vomiting
Vomiting at 15.7% is notably higher than placebo (3.9%). It's most likely to occur after overeating, consuming greasy food, or during the first days at a new dose. If vomiting is severe (more than 3 episodes in 24 hours) or persistent, contact your physician. Dehydration from vomiting can lead to acute kidney injury, especially in patients on concurrent diuretics or SGLT2 inhibitors.
Serious but Uncommon Side Effects
Pancreatitis
Acute pancreatitis occurred in 0.4% of liraglutide patients vs. 0.1% on placebo in the SCALE program. Symptoms include severe epigastric pain radiating to the back, nausea, and vomiting that worsens after eating. If suspected, stop the medication immediately and go to an emergency room.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Gallbladder Disease
Cholelithiasis and cholecystitis occurred in 2.5% of liraglutide patients vs. 1.0% on placebo. Rapid weight loss is an independent risk factor for gallstones regardless of how the weight is lost. Symptoms include right upper quadrant pain, especially after fatty meals, sometimes with fever.
Increased Heart Rate
Liraglutide 3.0mg increased resting heart rate by an average of 2.0 beats per minute compared to placebo. While modest, patients with pre-existing arrhythmias or tachycardia should be monitored.
Suicidal Ideation
The FDA required monitoring for suicidal thoughts and behavior with Saxenda. In SCALE trials, suicidal ideation was reported in 0.3% of liraglutide patients vs. 0.1% on placebo. While the absolute risk is low, patients with a history of depression or suicidal behavior should be monitored closely.
Thyroid C-Cell Tumors (Boxed Warning)
Liraglutide caused thyroid C-cell tumors in rodents at clinically relevant exposures. It's unknown whether this occurs in humans. The drug is contraindicated in patients with medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Who Discontinues Due to Side Effects?
In the SCALE trials, 9.8% of patients on liraglutide 3.0mg discontinued due to adverse events, compared to 3.8% on placebo. The most common reasons were GI symptoms (nausea, vomiting, diarrhea). Discontinuation was highest during the titration phase and the first 8 weeks at 3.0mg.
This means over 90% of patients who start liraglutide are able to continue at the maintenance dose. Proper titration and supportive management make a significant difference in tolerability.
Frequently Asked Questions
Do side effects get better over time?
Yes, for most patients. GI symptoms are most intense during dose escalation and the first few weeks at 3.0mg, then gradually improve. By month 3, the majority of patients report that side effects are mild or absent.
Can I take anti-nausea medication with liraglutide?
Your physician may prescribe ondansetron or another anti-emetic for severe nausea. Over-the-counter ginger supplements and vitamin B6 can also help. These don't interfere with liraglutide's weight-loss mechanism.
Is constipation on liraglutide permanent?
For some patients, constipation persists throughout treatment because it's related to liraglutide's effect on gut motility. Fiber supplements (psyllium husk is well-studied), adequate water intake, and regular physical activity can manage it effectively. Your physician may recommend an osmotic laxative if needed. managing constipation on GLP-1 medications
Does liraglutide cause hair loss?
Hair thinning was not a commonly reported adverse event in the SCALE trials. But rapid weight loss from any cause can trigger telogen effluvium, temporary shedding that typically begins 2 to 4 months after significant weight loss and resolves on its own. Eating adequate protein (0.8 to 1.0 grams per kg of body weight daily) helps minimize this risk.
Side Effect Support From FormBlends
At FormBlends, our physicians don't just prescribe liraglutide and move on. We actively manage side effects through proactive check-ins, dose adjustments, and practical guidance so you can stay on treatment and achieve your goals.
Having a tough time with side effects? Schedule a consultation with a FormBlends physician today.
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →